An Open Label, Prospective, Multicentric Study to Evaluate the Safety and Efficacy of BIOMAb-EGFRTM (Nimotuzumab) As Induction and Maintenance Therapy in Combination with Radiotherapy plus Temozolomide (Concomitant and Adjuvant) In Indian Patients with Glioblastoma Multiforme
Latest Information Update: 12 Nov 2019
Price :
$35 *
At a glance
- Drugs Nimotuzumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Biocon
- 15 Dec 2013 New trial record